Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 August 2021 | Story Department of Communication and Marketing

Dear Student, 

As from today (20 August 2021), all people 18 years and older are eligible to be vaccinated against COVID-19. Register on the COVID-19 Vaccination Programme registration portal to get the vaccine.

Individuals aged 18 and older can get vaccinated at sites  across the country – including the Universitas Academic Hospital in Bloemfontein and retail stores such as Clicks and Dischem.

Remember, you can walk into any vaccination site to register and vaccinate. 

Here is a list of registered vaccination sites closest to the University of the Free State campuses: 
- Boikhuco Old Age Home – Bloemfontein (Mangaung)
- MUCPP Community Health Centre in Rocklands – Bloemfontein (Mangaung)x
- Pelonomi Hospital – Bloemfontein (Mangaung) 
- Standard Bank Building – Bloemfontein (Mangaung)
- Universitas Academic Hospital – Bloemfontein (Mangaung)
- Botshabelo Hospital – Botshabelo (Mangaung)
- Seemahale Secondary School – Botshabelo (Mangaung)
- Dr JS Moroka Hospital – Thaba Nchu (Mangaung)
- Dihlabeng Regional Hospital – Bethlehem, Dihlabeng (Thabo Mofutsanyana)
- Thabo Thokoza Secondary School – Dihlabeng (Thabo Mofutsanyana)
- Thekolohelong Old Age Home – Maluti-A-Phofung (Thabo Mofutsanyana)
- Senorita Nthlabathi District Hospital – Mantsopa (Thabo Mofutsanyana)
- Nketoana District Hospital – Nketoana (Thabo Mofutsanyana)
- Phumelela District Hospital – Phumelela (Thabo Mofutsanyana)

Vaccines are an important part of stopping the spread of COVID-19. Vaccines reduce the risk of getting a disease by working with your body to build protection. 

Need more information on vaccines? Read our COVID-19 Vaccine Information booklet here.

Visit the UFS COVID-19 webpage for updated information. 


News Archive

Heart-valve studies receive international recognition
2017-07-11

 Description: Heart-valve studies  Tags: Heart-valve studies  

Prof Francis Smit, Head of the Department of
Cardiothoracic Surgery at the UFS, and Manager of the
Robert WM Frater Cardiovascular Research Centre, with
Kyle Davis, Mechanical Engineer at the centre.

Photo: Rulanzen Martin

Three heart-valve studies which have been developed at the Robert WM Frater Cardiovascular Research Centre at the School of Medicine at the University of the Free State (UFS) were recently presented in Monte Carlo at the conference of the prestigious global Heart Valve Society (HVS).

These studies are all headed by Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS, and Manager of the Robert WM Frater Cardiovascular Research Centre.
Prof Smit says the HVS is a combination of the former heart-valve societies of Europe and the US. “Studies on heart-valve disease, heart-valve-related products and operations, as well as the design and development of new valves were presented. There are both clinical and development divisions.

He says the study in which the hemodynamics of their redesigned mechanical poppet valve was compared to a commercial bi-leaflet mechanical heart valve, was named as the best poster presentation in the experimental valve development and numerical flow dynamics division. The study, which was presented by Kyle Davis, mechanical engineer at the centre, competed against some of the best heart-valve research units in the world.

The redesigned valve, based on the 1960s Cape Town poppet valve, has the potential to provide a low-cost solution for mechanical heart-valve replacement. It is possible to produce the titanium ring with 3-D printers and is, together with the silicon poppet valve, extremely inexpensive compared to current mechanical valve-manufacturing processes.
The advantages of this valve over current mechanical valves is that, due to the effective and laminar flow characteristics, as well as the simple locking mechanisms, there is a reduced chance of valve thrombosis, and the need for anti-clotting drugs is therefore limited.

It was also confirmed that the new valve more than meets the published FDA (Federal Drug Agency) requirements, which determine the minimum standards of valves for human use in the US.

The redesigned valve also has a very low platelet activation impact, which is responsible for platelet thrombosis and leads to valve thrombosis or strokes. This valve is another heart-valve project by the centre, which is also in the process of evaluating a tri-leaflet polyurethane valve developed by them.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept